Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-046134
Filing Date
2025-03-27
Accepted
2025-03-27 16:30:23
Documents
82
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K clsd-20241231.htm   iXBRL 10-K 2882875
2 EX-19 clsd-ex19.htm EX-19 89679
3 EX-23.1 clsd-ex23_1.htm EX-23.1 15533
4 EX-31.1 clsd-ex31_1.htm EX-31.1 15247
5 EX-31.2 clsd-ex31_2.htm EX-31.2 15210
6 EX-32.1 clsd-ex32_1.htm EX-32.1 10042
7 GRAPHIC img142427442_0.jpg GRAPHIC 192987
8 GRAPHIC img142427442_1.jpg GRAPHIC 46523
9 GRAPHIC img142427442_2.jpg GRAPHIC 395021
10 GRAPHIC img142427442_3.jpg GRAPHIC 193582
  Complete submission text file 0000950170-25-046134.txt   12822933

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20241231.xsd EX-101.SCH 1577546
85 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20241231_htm.xml XML 1699754
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37783 | Film No.: 25779832
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)